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Marina Lesnikova,1 Robert Jordan,1 Ya-Ju Laura Yang,1 Murad Y. Yunusov,1
Eustacia Zellmer,1 Shelly Heimfeld,1 Gopalakrishnan M. Venkataraman,1
Michael A. Harkey,1 Scott S. Graves,1,2 Rainer Storb,1,2 Barry E. Storer,1,3 Richard A. Nash1,27Cord blood transplantation (CBT) with units containing total nucleated cell (TNC) dose .2.5  10 /kg is
associated with improved engraftment and decreased transplant-related mortality. For many adults no single
cord blood units are available that meet the cell dose requirements. We developed a dog model of CBT to
evaluate approaches to overcome the problem of low cell dose cord blood units. This study primarily com-
pared double- versus single-unit CBT. Unrelated dogs were bred and cord blood units were harvested. We
identified unrelated recipients that were dog leukocyte antigen (DLA)-88 (class I) and DLA-DRB1 (class II)
allele-matched with cryopreserved units. Each unit contained#1.7 107 TNC/kg. Recipients were given 9.2
Gy total-body irradiation (TBI) and DLA-matched unrelated cord blood with postgrafting cyclosporine and
mycophenolate mofetil. After double-unit CBT, 5 dogs engrafted and 4 survived long term with 1 dominant
engrafting unit and prompt immune reconstitution. In contrast, 0 of 5 dogs given single-unit CBT survived
beyond 105 days (P 5 .03, log-rank test); neutrophil and platelet recovery was delayed (both P 5 .005)
and recipients developed fatal infections. This new large animal model showed that outcomes were improved
after double-unit compared to single-unit CBT. After double-unit CBT, the nonengrafted unit facilitates
engraftment of the dominant unit.
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Immune reconstitutionINTRODUCTION
Cord blood transplantation (CBT) has emerged as
an effective treatment for patients with malignant and
nonmalignant hematologic diseases. Clinical experi-
ence has shown that the infused cell dose and degree
of human leukocyte antigen (HLA) matching of cord
blood units are associated with engraftment and out-
come. Several studies have shown that total nucleated
cell (TNC) count and CD341 cell doses above mini-
mum thresholds are associated with improved engraft-1Clinical Research Division, Fred Hutchinson Cancer Re-
Center; 2Department of Medicine; and 3Department of
tistics, University of Washington, Seattle, Washington.
isclosure: See Acknowledgments on page 1097.
ffiliation for Szczepan Baran: Veterinary Bioscience Insti-
arleysville, PA.
dence and reprint requests: George E. Georges, MD,
al Research Division, Fred Hutchinson Cancer Research
r, 1100 Fairview Avenue North, Seattle, WA 98109
il: ggeorges@fhcrc.org).
anuary 15, 2010; accepted March 9, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.03.010ment and decreased transplant-related mortality
(TRM) [1-4]. As a result, several transplant center
guidelines recommended that the minimum
threshold cell dose for a single cord blood unit is at
least $2.5-3.0  107 TNC/kg for a 5/6 or 6/6 HLA-
matched unit (with low resolution typing at HLA-A
and -B and high resolution at 2DRB1) [5-7]. With
greater HLA disparity, the threshold cell dose is even
greater: the minimal cell dose for a single 4/6 HLA-
matched unit is at least $5.0  107 TNC/kg [6]. For
many adults and older children no single units are
available that meet these cell dose requirements. To
overcome this limitation, investigators at the Univer-
sity of Minnesota introduced double-unit cord trans-
plantation in which 2 cord units are infused
simultaneously to increase the total infused cell dose
[8,9]. Nonrandomized clinical studies indicate that
compared to low cell dose single-unit CBT, double-
unit CBT appears to have increased engraftment and
decreased transplant related mortality [8,10,11].
Many transplant centers now routinely use double-
unit CBT for adults, and there is currently a random-
ized clinical trial in progress comparing single- versus
double-unit CBT in children. After double-unit CBT,
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emerges as the sole source of long-term hematopoiesis.
Although TNC, CD341, CD31 cell count, sex-
mismatch, ABO blood group, HLA mismatch, and or-
der of infusion have been evaluated, to date, no factors
have been identified that consistently predict which
unit will emerge as the dominant engrafting unit
[12]. Recent data, however, suggest the unit with
higher CD341 cell viability at the time of thawing pre-
dicts the subsequent dominant engrafting unit, partic-
ularly when the nonengrafting unit has\75% CD341
viability [13].
Because of limitations with the clinical trials of
CBT, questions still remain as to the benefit of
double-unit CBT and the biologic determinants of en-
graftment following double-unit CBT. To address
these questions we aimed to develop a large animal
model of CBT. Because of the long track record of suc-
cessful translation of experimental findings in the out-
bred dog model to the clinic [14,15], we investigated if
the dog model of CBT could begin to address
questions of cell dose and major histocompatibility
complex (MHC) barriers to engraftment and survival
after high dose total-body irradiation (TBI).MATERIAL AND METHODS
Animals and Surgical Procedures
All procedures and research protocols were ap-
proved by the Institutional Animal Care and Use
Committee of the Fred Hutchinson Cancer Research
Center (FHCRC). Research and animal housing was
conducted according to the principles outlined in the
Guide for Laboratory Animal Facilities and Care prepared
by theNational Academy of Sciences andNational Re-
search Council. Dogs were raised at the FHCRC or
obtained from commercial kennels licensed by the
U.S. Department of Agriculture. Adult female, out-
bred beagle and mixed-breed minimongrel and hound
dogs from which cord blood units were harvested
weighed 8.0 to 38.0 (median: 10.4) kg and were 18-
122 (median: 23.5) months old. CBT recipient beagle
and mixed breed dogs weighed 7.0-32.0 (median: 9.8)
kg and were 9.5-22.0 (median: 14.4) months old. All
dogs were examined at least twice daily. Recipient
dogs were euthanized after transplantation when es-
tablished clinical criteria were met for poor condition
with infectious complications.
Details of the canine cord blood unit collection
and characterization are described in the Supplemental
Materials/Methods section (available online). Briefly,
at days 53 to 58 of gestation (estimated at 3-6 days be-
fore full term), gravid dogs were placed under general
anesthesia and underwent a Cesarean section proce-
dure. There were 2 to 12 fetuses per gravid female;
each fetus had a placenta that was separate and distinctfrom the other littermates. Throughout the fetal/cord
blood collection procedure, each fetus was closely
monitored for complete anesthesia. Because of the
small size of the canine umbilical cord, blood collec-
tion from the isolated, clamped umbilical cord resulted
in insufficient cell dose yield needed for subsequent
transplantation experiments. The CD34 cell and col-
ony forming unit (CFU) content of fetal jugular vein
and umbilical cord blood were equivalent (Figure S.1
and Tables S.1 and S.2). To minimize the number of
animals used as cord blood donors, and to increase
the cell dose yield from each fetus, we combined fetal
and umbilical cord blood as the source of blood cells
for all subsequent experiments. For this manuscript,
CBT in dogs is defined as the transplantation of the
combined fetal and umbilical cord blood.
Immediately after collection of each venous fetal/
cord blood unit, aliquots of cord blood were collected
for DLA typing and hematologic characterization. Im-
munophenotyping of blood was completed (Tables S.3
and S.4) [16]. After the cord blood unit cell dose was
determined, the cells were cryopreserved.
DLATyping
DLA-identical sibling units for CBT were chosen
on the basis of complete family studies showing iden-
tity for highly polymorphic MHC associated class I
and II microsatellite markers and by direct sequencing
of DLA-DRB1 [17,18]. Initial experiments with DLA-
identical siblings used recipient dogs from a prior litter
of the same breeding pair. DLA-matched unrelated
units for CBT were chosen on the basis of direct se-
quencing for both DLA DRB1 (class II) and DLA-88
(class I) allelic identity [18,19]. Breeding to generate
the unrelated cord blood units was performed after
the DLA type of the female and male was
determined and dogs heterozygous for the most
common DRB1 alleles, 00101, 00102, 00201, 00601,
00801, and 01501 were selected. The breeding pairs
were unrelated by at least 6 generations. The CBT
recipients were selected after DLA allele sequencing
of adult dogs. Subsequently, DLA-matched unrelated
recipient dogs were identified from randomly selected
dogs that were unrelated to the cord blood donors by
at least 6 generations in a separate, genetically diverse
outbred colony.
Transplantation
Total-body irradiation (TBI) 9.2 Gray (Gy) was
delivered as a single fraction at 7 cGy/min from a 4
MEV (for the initial experiments with DLA-identical
siblings units) and, more recently, with a 6-MEV linear
accelerator (CLINAC 4/80 and CLINAC 600 C/D,
respectively, Varian Associates, Palo Alto, CA). This
is considered to be a myeloablative TBI dose [20,21].
CBT consisted of intravenous infusions of unwashed,
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 107 nucleated white blood cells (WBCs) per
kilogram recipient body weight (TNC dose was
obtained prior to cryopreservation and excluded
nucleated red blood cells [RBCs]). The day of CBT
was designated day 0. Cord blood unit CD341 cells
were analyzed for viability after thawing. Flow
cytometric evaluation was performed using the
International Society of Hematotherapy and Graft
Engineering (ISHAGE) gating strategy [22] with mi-
nor modifications to maximize the detection of live
and dead cells (Figure S.2) [13].
Recipients were given postgrafting immunosup-
pression for prevention of graft rejection and graft-
versus-host disease (GVHD). Cyclosporine (CSP) 15
mg/kg orally (p.o.) twice daily (b.i.d.) was given starting
from day 23 to day 149. Mycophenolate mofetil
(MMF) 5 mg/kg subcutaneous b.i.d. was given from
day 0 starting after TBI to day 13, the dose was
increased to 7.5 mg/kg b.i.d. on days 14 to 42. CSP
dose was adjusted based on weekly predose levels with
a target range of 250 to 500 ng/mL. To prevent graft
rejection among recipients of single-unit unrelated
CBT, the CSP dose was extended from days 50 to 98
at 7.5 mg/kg p.o. b.i.d., and MMF was continued from
days 43 to 84 at 3.75 mg/kg subcutaneous b.i.d. Re-
combinant caninegranulocyte colony stimulating factor
(G-CSF) 5 mg/kg subcutaneous b.i.d. was initiated after
TBI and continued until sustained recovery of absolute
neutrophil count (ANC) .1000/mL for 3 consecutive
days. Supportive care included prophylaxis with the
oral antibiotic enrofloxacin from the day of TBI.
Broader antibiotic coverage was administered with
ceftazidime and vancomycin plus additional antibiotics
as clinically indicated when ANC declined to below
500/mL and fever developed. LactatedRinger’s solution
8 to 10 mL/kg intravenous was administered at least
twice daily after TBI until there was complete clinical
recovery (additional details are described in the Supple-
mentalData# 1:Materials andMethods section). Irradi-
ated blood transfusions [23] were given either when
platelet counts declined below 6 109/L or when pete-
chiae and ecchymoses of skin and mucous membranes
were observed or when the hematocrit was\24%.
Assessment of Engraftment and Chimerism
The contributions of recipient and donor cells to
peripheral blood and bone marrow were quantified
by fluorescent variable number tandem repeat
(VNTR) analysis [24]. Because some recipients
received cells from 2 or 3 donor units, multiple loci
were analyzed to fully distinguish the recipient and
each donor unit for each transplant.
Immune Reconstitution
In vitro immune functions of recipients were mea-
sured by mixed lymphocyte reaction (MLR), witha panel of 3 stimulators and autologous PBMC to gen-
erate a stimulation index [25]. In addition, peripheral
blood CD3, CD4, CD8, and CD21 phenotypes were
determined by fluorescence cytometric analysis with
fluorescein-conjugated CA17.6F9, and phycoerythrin
conjugated CA13.1E4, CA9.JD3, and CA2.1D6, re-
spectively [24]. Analysis was performed on a FACSCa-
libur or FACScan flow cytometer (Beckton Dickinson,
San Jose, CA) and analyzed with FlowJo software
(Treestar, Ashland, OR). Antibody responses to neo-
antigen sheep red blood cells (SRBCs) were deter-
mined at 148 to 248 days after transplantation [26,27].
Statistical Analysis
The log-rank test was used for comparison of sur-
vival and time to count recovery between 2 groups.
Wilcoxon rank sum test was used for comparison of
transfusion support.McNemar’s test was used for eval-
uating the cell viability and dominant unit engraftment
outcome.RESULTS
DLA-Identical Sibling Cord Blood
Transplantation
For the initial experiments, cord blood units were
infused into DLA-identical siblings from a prior litter
of the same breeding pair. Each unit contained 0.3-0.8
 107 TNC/kg. Because of the low total leukocyte
dose in each unit, we combined 2 to 4 DLA-identical
units for each CBT. Table 1 summarizes the results.
Five dogs received 2 to 4 units of DLA-identical
cord blood grafts following 9.2 Gy TBI. Four dogs en-
grafted and survived long term with stable donor en-
graftment and evidence of robust immune
reconstitution (Figure S.3). One dog was euthanized
on day113 because of sepsis. None of the dogs devel-
oped GVHD. The median time to engraftment with
sustained ANC.500/mL was 28 (range: 21-32) days.
The median time to engraftment with sustained plate-
lets.50,000/mLwas 58 (range: 35-99) days.Mixed he-
matopoietic chimerism was initially observed in all
recipient dogs, although 1 dominant unit emerged
that eventually exceeded .80% PBMC and .90%
granulocyte chimerism.
Next, we asked if infusion of 1 DLA-identical cord
blood unit with a low cell dose could engraft and pro-
mote survival after 9.2 Gy TBI. Three dogs underwent
single-unit CBT. Two dogs were euthanized early be-
cause of sepsis, on days 115 and 17, respectively, with
findings of marrow aplasia and hemorrhage at nec-
ropsy (Table 2). The 1 evaluable recipient engrafted
with sustained ANC .500/mL on day 34 and platelets
.50,000/mL on day 63. This surviving recipient devel-
oped .98% donor PBMC chimerism by 1 year and
had successful immune reconstitution (Figure S.3).
Table 1. DLA-Identical Sibling Multiple Unit Cord Blood Transplantation
Recipient
Dog #
Donor
Unit #
DLA-DRB1
Alleles
TNC
(107/kg)
CD34
(105/kg)
CD3
(106/kg)
% CD34+
Viable
% PBMC
Chimerism at 1 Year
Transplant
Outcome
G567 G464 u.5 00401/01301 0.6 0.6 1.3 ND 92 Alive >3 years
G464 u.9 0.6 0.4 1.9 6
G568 G464 u.1 01301/01501 0.4 0.3 0.5 69 NE ET day 13
G464 u.2 0.3 0.2 1.2 75 Sepsis, E. coli
G464 u.6 0.4 0.4 0.7 70
G464 u.10 0.3 0.2 0.5 71
G569 G464 u.4 00401/01901 0.6 0.5 2.6 ND 7 Alive >3 years
G464 u.11 0.4 0.4 1.2 89
G464 u.12 0.4 0.4 0.8 3
G570 G464 u.3 01501/01901 0.6 0.5 1.6 95 99 Alive >3 years
G464 u.7 0.4 0.4 1.0 83 0
G545 E333 u.1 00801/01401 0.5 0.4 0.9 98 80 Alive >3 years
E333 u.2 0.6 0.6 1.6 86 20
TNC indicates total nucleated cells; kg, kilogram (recipient weight); PBMC, peripheral blood mononuclear cell; ET, euthanized because of meeting de-
fined criteria of poor condition (indicated by day after transplantation and cause); ND, not done; NE5 not evaluable.
The donor unit is identified by maternal dog number followed by the cord/fetal unit in the order of collection at the time of Cesarean section. Dog
leukocyte antigen (DLA) alleles indicate nucleotide sequence nomenclature for DLA-DRB1 (MHC class II) or DLA-88 (MHC class I) (http://www.ebi.
ac.uk/ipd/mhc/). The cord blood units were DLA-identical with each other and the recipient. Boldface indicates dominant engrafting cord blood unit.
There was significant unit-to-unit variability in the percent nucleated red blood cells (nRBC). Therefore, the TNC shown excludes all nRBC. yr.5 years.
The % viable CD34+ cells were determined by flow cytometry with an aliquot from the unit after thawing.
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that the infusion of a larger cell dose or multiple units
of DLA-identical cord blood resulted in a greater like-
lihood of sustained engraftment and survival.
Unrelated Canine Cord Blood Bank
To develop a dog model that more closely ad-
dressed the clinical problem of single-unit low cell
dose unrelated CBT for adult human patients, we
next focused on the development of a cord blood
bank with commonClass II alleles. After breeding a to-
tal of 30 dog pairs, there were 187 cord blood units col-
lected and cryopreserved, representing 15 different
combinations of the 2 most polymorphic MHC-class
I and II alleles, DLA-88 and DRB1, respectively.
Next, we identified unrelated transplant recipients
that were DLA-matched for all DRB1 and DLA-88 al-
leles. The recipients were obtained from a separate,
genetically diverse, outbred colony.
DLA-Matched Unrelated Cord Blood
Transplantation
For the DLA-matched unrelated CBT model, we
first infused 2 cord blood units into recipients. Table
3 summarizes the results. Five dogs received double-
unit DLA-matched unrelated CBT following 9.2 Gy
TBI. Each unit contained 0.4-1.7  107 TNC/kg.
All 5 dogs engrafted, but 1 dog was euthanized on
day 50 because of acute pneumonitis. None of the
dogs developed GVHD. The median time to engraft-
ment with sustained ANC.500/mLwas 17 (range: 16-
19) days (Figure 1A). The median time to engraftment
with sustained platelets .50,000/mL was 35 (range:
29-38) days. Mixed hematopoietic chimerism was ini-
tially observed in all recipient dogs, although thereemerged 1 dominant unit that exceeded .80%
PBMC and .90% granulocyte chimerism by day 35
to 133 after CBT (Figure 2). The TNC, CD34,
CD3, CD4, and CD8 cell dose, sex mismatch and or-
der of infusion did not predict the dominant engrafting
unit. However, combining the available data from both
related and unrelated double-unit CBT recipients, the
viability of the CD341 cells at the time of thawing and
infusion of the 2 units appeared to predict the engraft-
ing unit. Among the 7 evaluable recipients (Tables 1
and 3 and Figure 2), the unit with the greatest
CD341 viability at the time of infusion was subse-
quently the dominant engrafting unit, P 5 .03.
All surviving dogs had immune reconstitution with
recovery of T cell function, measured by mixed lym-
phocyte reaction assay (data not shown), antibody re-
sponse to sheep red blood cells and T cell subset
recovery to pretransplant levels developing between
150 to 250 days after CBT (Figure 3).
Next, we asked if infusion of 1 unit of low cell dose
unrelated cord blood could achieve engraftment and
survival. Five dogs received 1 unit of DLA-matched
unrelated cord blood following 9.2 Gy TBI (Table 4
and Figure 1B). Each unit contained 0.6-0.9  107
TNC/kg. One dog was euthanized because of pneu-
monitis on day 11 and was not evaluable for engraft-
ment. Four dogs achieved first day of ANC .500/mL
at a median of 24 (range: 21-28) days after CBT. How-
ever, 2 dogs had subsequent graft rejection, remained
neutropenic, then developed bacterial sepsis and
were euthanized on days 70 and 74, respectively. One
dog had neutrophil engraftment but remained platelet
transfusion dependent and developed pneumonitis and
was euthanized on day 54. Only 1 dog had neutrophil
and platelet engraftment with recovery on day 21 and
68, respectively, but developed sepsis and was
Table 2. DLA-Identical Sibling Single-Unit Cord Blood Transplantation
Recipient
Dog #
Donor
Unit #
DLA-DRB1
Alleles
TNC
(107/kg)
CD34
(105/kg)
CD3
(106/kg)
% PBMC
Chimerism at 1 year
Transplant
Outcome
G730 G692 u.8 00201/00102 0.8 0.8 1.4 98 Alive >2.5 years
G732 G692 u.7 00201/01501 0.4 0.4 1.0 NE ET day 15
Sepsis
G734 G692 u.9 00201/00102 0.4 0.3 0.7 NE ET day 17
Sepsis M. morganii
TNC indicates total nucleated cells; kg indicates kilogram (recipient weight); PBMC, peripheral blood mononuclear cell; ET, euthanized because of meet-
ing defined criteria of poor condition (indicated by day after transplantation and cause); NE, not evaluable.
The donor unit is identified by maternal dog number followed by the cord/fetal unit in the order of collection at the time of Cesarean section. Dog
leukocyte antigen (DLA) alleles indicate nucleotide sequence nomenclature for DLA-DRB1 (MHC class II) or DLA-88 (MHC class I) (http://www.ebi.
ac.uk/ipd/mhc/). The cord blood units were DLA-identical with the recipient. There was significant unit-to-unit variability in the percent nucleated red
blood cells (nRBC). Therefore, the TNC shown excludes all nRBC.
1094 Biol Blood Marrow Transplant 16:1090-1098, 2010G. E. Georges et al.euthanized on day 105. In summary, all 5 recipients of
single-unit CBT died because of infectious complica-
tions, despite intensive supportive care and prompt in-
tervention with broad-spectrum antibiotics.
Compared to unrelated double-unit CBT, single-
unit CBT was associated with significantly worse
survival (P5 .03). The times to neutrophil and platelet
recovery were markedly delayed in single unit recipi-
ents, P 5 .005 and .005, respectively. The differences
in supportive care given to the 2 cohorts were also sig-
nificant. The median number of blood transfusions
given to unrelated double versus single cord blood
unit recipients was 4 versus 17, respectively, P 5 .01.DISCUSSION
We have developed a large animal model of CBT.
The initial studies were performed with DLA-
identical sibling cord blood units to develop the
methods and establish the feasibility of CBT in the
dog model. We showed that transplantation of multi-Table 3. Double-Unit DLA-Matched, Unrelated Cord Blood Transp
Recipient Cord Bloo
DLA Alleles Cell Do
Dog # DRB1 Class I
Donor
Unit #
TNC
(107/kg)
CD3
(105/
G877 00102/01501 01201/50201 G879 u.5
G833 u.4
0.5 0.5
1.7 1.1
G878 00201/01501 01201/50801 G756 u.3
G755 u.3
0.8 0.4
1.1 0.7
G903 00201/00102 50201/50801 G755 u.2
G755 u.4
1.2 0.6
1.4 1.0
G905 00102/01501 01201/50201 G779 u.3
G833 u.8
0.9 1.1
1.3 0.8
G910 00102/01501 01201/50201 G879 u.1
G881 u.4
0.4 0.3
1.4 0.8
TNC indicates total nucleated cells; kg, kilogram (recipient weight); PBMC, pe
fined criteria of poor condition (indicated by day after transplantation and cau
The donor unit is identified by maternal dog number followed by the cord/fe
leukocyte antigen (DLA) alleles indicate nucleotide sequence nomenclature fo
ac.uk/ipd/mhc/). The donor units were DLA-matched (for DLA-DRB1 and DLA
grafting cord blood unit. The TNC shown excludes all nucleated red blood cell
aliquot from the unit after thawing.ple cord blood units rescued dogs from myeloablative
TBI, and that although all the units were DLA-
identical with each other and the recipient, 1 unit even-
tually became the dominant source of hematopoiesis.
In contrast, only 1 of the 3 recipients of a single
DLA-identical littermate cord blood unit survived.
However, the prolonged time to engraftment and early
infectious complications and the limited availability of
DLA-identical littermate cord blood units precluded
definitive comparison between single and multiple
units of CBT.
To more accurately model the clinical setting of
low cell dose unrelated CBT for adult human patients,
we next developed a dog cord blood bank with nonho-
mozygous combinations of the 6 most common DLA-
DRB1 alleles. The allelic sequences of DLA-DRB1
andDLA-88, themost polymorphic canineMHCclass
II and class I alleles, respectively, were determined for
each collected cord blood unit, and unrelated recipi-
ents matched for both DRB1 and DLA-88 alleles
were identified.lantation
d Unit Transplant Outcome
se
% PBMC
Chimerism
at 1 Year
4
kg)
CD3
(106/kg)
% CD34+
Viable Graft Status
1.4 98 96 Engrafted, alive >2 years
4.1 77 0
1.9 91 6 Engrafted, alive >2years
3.5 97 91
3.8 90 94 Engrafted, alive >2 years
4.5 85 0
3.0 92 N/A Engrafted
ET day 50 pneumonitis2.7 87 N/A
1.2 85 10 Engrafted, alive >2 years
1.7 85 90
ripheral blood mononuclear cell; ET, euthanized because of meeting de-
se); N/A, not applicable.
tal unit in the order of collection at the time of Cesarean section. Dog
r DLA-DRB1 (MHC class II) or DLA-88 (MHC class I) (http://www.ebi.
-88) with each other and the recipient. Boldface indicates dominant en-
s. The % viable CD34+ cells were determined by flow cytometry with an
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Figure 1. The absolute neutrophil count (ANC) and platelet count per microliter (log10 scale) from dogs receiving unrelated cord blood transplanta-
tion (CBT) on day 0 after 9.2 Gy TBI. (A) Double-unit CBT group. (B) Single-unit CBT group. Each line/symbol represents blood counts from individual
dogs. ET, euthanized because of meeting defined criteria of poor condition after transplantation (for details, see Tables 3 and 4).
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dose were used to model the clinical situation in which
the best matched unrelated cord blood unit was well
below the standard TNC/kg doses generally accepted
for clinical CBT.With double-unit unrelated CBT, all
5 recipients engrafted and 1 unit contributed.80% of
myeloid and lymphoid hematopoiesis within 4 to 16
weeks after CBT.
Perhaps because of the limited number of animals
studied, we were unable to identify if greater TNC,
CD34, or T cell dose predicted which unit became
the dominant contributor to engraftment. However,
in accordance with a recent report by Scaradavou
et al. [13], we observed that among the evaluable recip-
ients of double-unit CBT, the unit with the greatest
CD341 cell percent viability at the time of thawing
and infusion predicted the subsequent dominantmsir
e
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Figure 2. Serial chimerism analyses from peripheral bloodmononuclear cells f
The first infused donor unit had the lower total cell dose. Each cord blood unit c
for the dominant unit was consistently $% PBMC chimerism (data not shownengrafting unit. Another emerging concept is that
there is CD8 T cell-mediated competition between
the 2 donor units that determine the dominant engraft-
ing unit [28]. Further studies in this CBTmodel will be
needed to understand the engraftment process,
although we can speculate that the CD341 viability
may reflect the overall health of the thawed units,
and the immune mediated competition between units
favors the unit with the greater cellular viability.
After double-unit CBT immune reconstitution
was relatively prompt, with various measures of T
cell recovery returning to pretransplant levels within
150 to 250 days, and subsequently remaining stable.
In contrast, despite optimal intensive supportive
care, single-unit DLA-matched unrelated CBT did
not achieve reliable engraftment, and all 5 dogs died
within 105 days after transplantation. The time to400 600
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Figure 3. (A) Immune recovery of Tand B cell subsets in 4 dogs after double-unit unrelated cord blood transplantation (CBT). Shaded region indicates
normal range of values (median 6 1 standard deviation from 20 untreated dogs). (B) Primary and secondary antibody titer response against the neo-
antigen sheep red blood cells injected on day 1148-184 and 1218-248 after CBT, respectively.
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unit CBT was significantly delayed compared to
double-unit CBT. Similarly, even though neutrophil
engraftment occurred in 2 recipients, immune recov-
ery was inadequate to help protect against bacterial
pathogens despite very close clinical monitoring and
prompt, aggressive treatment with broad spectrum an-
tibiotics. Although the prolonged duration of CSP/
MMF may have contributed to the poor outcome of
the single-unit CBT recipients, data from other exper-
iments suggested this was unlikely. In previous studies
after DLA-identical hematopoietic cell transplanta-
tion we showed that extending postgrafting CSP im-
munosuppression successfully prevented graft
rejection and did not increase infectious complicationsTable 4. Single-Unit DLA-Matched, Unrelated Cord Blood Transpl
Recipient Cord B
DLA Alleles
Dog # DRB1 Class I Donor Unit
TNC
(107/kg)
G940 00102/01501 01201/50201 G881 u.5 0.9
G944 00102/00201 50801/50201 H021 u.4 0.6
H160 00102/01501 01201/50201 G881 u.6 0.8
H162 00102/01501 01201/50201 H019 u.9 0.6
H164 00102/00201 50801/50201 H021 u.2 0.6
TNC indicaters total nucleated cells; kg, kilogram (recipient weight); ET, euthan
day after transplantation and cause).
The donor unit is identified by maternal dog number followed by the cord/fe
leukocyte antigen (DLA) alleles indicate nucleotide sequence nomenclature fo
ac.uk/ipd/mhc/). The donor units were DLA-matched with the recipient. The[29]. In another cohort of recipient dogs given DLA-
mismatched CBT, prolongation of CSP/MMF pre-
vented graft rejection, improved survival, and did not
increase the risk of infectious death (manuscript in
preparation).
These results established a minimum threshold
cell dose required for engraftment and survival after
unrelated CBT in this dog model that was within the
range of 1.0-1.8  107 TNC/kg. The minimum
threshold cell dose for CBT engraftment in DLA-
identical siblings appears to be slightly lower (\0.8
 107 TNC/kg). This may be because of the greater
genetic disparity between unrelated donors and recip-
ients. Because of the cost limitations of the experimen-
tal large animal model, we did not test if a single-unitantation
lood Unit
Cell Dose Transplant Outcome
CD34
(105/kg)
CD3
(106/kg)
Day of Euthanasia, Graft
Status, Necropsy Findings
0.5 2.0 ET day 74, Graft
rejection.
Sepsis: enterococcus sp., staphylococcus
0.7 0.7 ET day 11, Graft NE.
Septic pneumonitis,
multiple organisms
0.6 1.0 ET day 105, Engrafted.
Sepsis: E. coli, hemorrhage
0.6 0.7 ET day 54, Neutrophil
graft.
Pneumonitis, sepsis: enterococcus sp.
0.8 1.1 ET day 70, Graft
rejection.
Sepsis: Pseudomonas, enterococcus sp.
ized because of meeting defined criteria of poor condition (indicated by
tal unit in the order of collection at the time of Cesarean section. Dog
r DLA-DRB1 (MHC class II) or DLA-88 (MHC class I) (http://www.ebi.
TNC shown excludes all nucleated red blood cells.
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ficient for engraftment and survival. We showed that
after double-unit CBT the unit that became the dom-
inant engrafting unit had a cell dose that would have
been predicted to be insufficient to achieve engraft-
ment and survival if given as a single unit. Comparing
double- versus single-unit CBT, it appears that the
nonengrafting unit enhanced the engraftment of the
dominant unit with more rapid recovery of neutrophils
and platelets and a lower rate of graft rejection. The
data suggest that the nonengrafting unit had an effect
equivalent to increasing the total cell dose of the
engrafting unit.
Our results in this model are very relevant to the
clinical experience with CBT. Clinical use of CBT
for adults was limited for several years because trans-
plantation of single-unit, low cell dose cord blood
was associated with high TRM ranging from 40% to
68% [11,30,31]. There are relatively few single units
with a sufficiently high cell dose available for adults
[8]. Similar to the findings of our study, the introduc-
tion and success of double-unit CBT in nonrandom-
ized phase II clinical trials resulted in an increased
number of adult patients eligible for transplantation
since the combination of 2 units, each with a low cell
dose, reached the safer threshold dose of 3  107
TNC/kg [5-8,10]. A randomized clinical CBT study
directly comparing 1 versus 2 low cell dose units is
not feasible, because of the concern of high TRM in
low cell dose single-unit recipients. Instead, the results
of our study strongly support the use of increased cell
dose achieved with double-unit CBT.
The significance of this CBT model may be en-
hanced as we address other important issues facing
clinical CBT. Strategies to improve engraftment and
survival after partially MHC-mismatched CBT can
now be directly studied in dogs to reduce the risk for
patients participating in clinical studies. This model
allows us to test if 1 (or more) MHC-mismatched
unit(s) can be given to promote engraftment of a single
MHC-matched or partially matched low cell dose
unit. Additional questions suited for study in this
double-unit CBTmodel include how to ensure the en-
graftment of the best MHC-matched unit and how to
prevent an MHC-mismatched unit from becoming
dominant and causing GVHD. Other approaches
that can be rigorously tested in this model include
the infusion of ex vivo expanded cord blood cells to fa-
cilitate engraftment of low cell dose units and treat-
ment to enhance the homing of stem cells to the
bone marrow.
In addition to the relevance of this model for clin-
ical CBT, another significant impetus for this project
came from the need to develop better treatment proto-
cols for victims of radiation accidents or nuclear ter-
rorist attacks. Cord blood is a stockpiled, readily
available ‘‘off-the-shelf’’ resource that can be rapidlyused in the setting of accidental high-dose TBI expo-
sure (ranging from 7 to 11 Gy). For radiation victims
with the hematopoietic syndrome and low probability
of endogenous hematopoietic recovery, CBT is an im-
portant therapeutic treatment option. This dog CBT
model will allow us to address several critical questions
including: what additional conditioning is needed with
increasing time delay between radiation exposure and
CBT? What is the optimal postgrafting immunosup-
pression? What are the acceptable parameters of
MHC mismatch for supplemental cord blood units
when the cell dose of the best-matched cord blood
unit is below recommended levels?Most of these ques-
tions are also relevant to the further clinical develop-
ment of CBT for patients with malignant and
nonmalignant hematologic diseases.ACKNOWLEDGMENTS
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